Skip to content

Study · In vitro (cells) · 1996

3 results

Characterization of pituitary adenylate cyclase-activating polypeptide 38 (PACAP38)-, PACAP27-, and vasoactive intestinal peptide-stimulated responses in N1E-115 neuroblastoma cells.

Chik CL, Inukai T, Ogiwara T, Boyd H, Li B, Karpinski E, Ho AK

Journal of neurochemistry1 Sept 1996Cited by 8 (Europe PMC)

PMID8752106 (opens in a new tab)DOI10.1046/j.1471-4159.1996.67031005.x (opens in a new tab)PepBankPUB-08752106
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In N1E-115 neuroblastoma cells, VIP stimulated cAMP accumulation less potently than PACAP38 and PACAP27.

    In plain wordsIn cells, VIP raised a cell-signalling molecule, but less strongly than the related peptides PACAP38 and PACAP27.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasecAMP accumulation
    Study

    n: not reported in source

    N1E-115 neuroblastoma cells
    Comparator
    PACAP38 and PACAP27
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect of VIP on cAMP accumulation was less potent.
    1 context sentence
    Summary · context
    In this study, the effects of three related peptides, pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), PACAP27, and vasoactive intestinal peptide (VIP), on cyclic AMP (cAMP) accumulation and intracellular Ca2+ concentration ([Ca2+]i) were compared in N1E-115 cells.
  2. 02LabIn vitro (cells)Activity measurement

    In intact N1E-115 cells, VIP did not inhibit the binding of 125I-PACAP27, unlike PACAP38 and PACAP27.

    In plain wordsIn cells, VIP did not displace PACAP27 from its binding sites, unlike PACAP38 and PACAP27.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeInhibition of 125I-PACAP27 binding
    Study

    n: not reported in source

    N1E-115 neuroblastoma cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding of 125I-PACAP27 to intact cells was inhibited by PACAP38 and PACAP27 (IC50 values of 0.44 and 0.55 nM, respectively) but not by VIP.
    1 context sentence
    Summary · context
    In this study, the effects of three related peptides, pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), PACAP27, and vasoactive intestinal peptide (VIP), on cyclic AMP (cAMP) accumulation and intracellular Ca2+ concentration ([Ca2+]i) were compared in N1E-115 cells.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism

    In N1E-115 cells, ionomycin increased the cAMP accumulation caused by VIP, PACAP38 and PACAP27.

    In plain wordsIn cells, the calcium-raising agent ionomycin increased the cAMP signal caused by VIP and by the two PACAP peptides.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseEffect of ionomycin on peptide-stimulated cAMP accumulation
    Study

    n: not reported in source

    N1E-115 neuroblastoma cells
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Ionomycin increased the cAMP accumulation caused by all three peptides.
    1 context sentence
    Summary · context
    In this study, the effects of three related peptides, pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), PACAP27, and vasoactive intestinal peptide (VIP), on cyclic AMP (cAMP) accumulation and intracellular Ca2+ concentration ([Ca2+]i) were compared in N1E-115 cells.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.